Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...

Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...

COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...

Thank you for standing by, and welcome to the COMPASS Pathways' first quarter 2024 investor call. [Operator instructions] As a reminder, today's program is being recorded. And now, I'd like to ...

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For ...

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.